Literature DB >> 27347354

Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.

Saumya Reddy Kankanala1, Rafay Syed1, Quan Gong2, Boxu Ren2, Xiaoquan Rao1, Jixin Zhong1.   

Abstract

The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase in hospitalization for heart failure in diabetic patients who received the DPP4 inhibitor saxagliptin. There has been substantial increase in knowledge on the heart failure effect of DPP4 inhibition since 2013. This review will summarize the role of the DPP4/incretin axis in heart failure and discuss the findings from recent large scale clinical trials assessing the effects of DPP4 inhibitors on heart failure.

Entities:  

Keywords:  DPP4; cardiovascular outcomes; heart failure; incretin

Year:  2016        PMID： 27347354      PMCID： PMC4891459     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  71 in total

1.  Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Authors:  Rikje Ruiter; Loes E Visser; Myrthe P P van Herk-Sukel; Petronella H Geelhoed-Duijvestijn; Sandra de Bie; Sabine M J M Straus; Peter G M Mol; Silvana A Romio; Ron M C Herings; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.

Authors:  Yanping Li; Yang Hu; Sylvia H Ley; Swapnil Rajpathak; Frank B Hu
Journal:  Diabetes Care       Date:  2014-08-22       Impact factor: 19.112

4.  Lactic acidosis in patients with diabetes treated with metformin.

Authors:  R I Misbin; L Green; B V Stadel; J L Gueriguian; A Gubbi; G A Fleming
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

5.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.

Authors:  Minsuk Kim; Mathew J Platt; Tadao Shibasaki; Susan E Quaggin; Peter H Backx; Susumu Seino; Jeremy A Simpson; Daniel J Drucker
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

6.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

7.  Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice.

Authors:  Erin E Mulvihill; Elodie M Varin; John R Ussher; Jonathan E Campbell; K W Annie Bang; Tahmid Abdullah; Laurie L Baggio; Daniel J Drucker
Journal:  Diabetes       Date:  2015-12-15       Impact factor: 9.461

8.  Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure.

Authors:  S Sundararaman; T J Miller; J M Pastore; M Kiedrowski; R Aras; M S Penn
Journal:  Gene Ther       Date:  2011-04-07       Impact factor: 5.250

Review 9.  DPP4 in Diabetes.

Authors:  Diana Röhrborn; Nina Wronkowitz; Juergen Eckel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561

Review 10.  Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease.

Authors:  Jixin Zhong; Sanjay Rajagopalan
Journal:  Front Immunol       Date:  2015-09-25       Impact factor: 7.561
View more
  9 in total

Review 1.  Effect of glucose-lowering therapies on heart failure.

Authors:  Michael Nassif; Mikhail Kosiborod
Journal:  Nat Rev Cardiol       Date:  2018-01-25       Impact factor: 32.419

Review 2.  The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies.

Authors:  Vaia Lambadiari; George Dimitriadis; Nikolaos P E Kadoglou
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 3.  Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure.

Authors:  Yvonne May Fen Chia; Tiew-Hwa Katherine Teng; Chanchal Chandramouli; Jonathan Yap; Michael MacDonald; Carolyn S P Lam
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 4.  DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.

Authors:  Chayakrit Krittanawong; Andrew Xanthopoulos; Takeshi Kitai; Natalia Branis; HongJu Zhang; Marrick Kukin
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

5.  Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.

Authors:  Christie A Schumacher; Elizabeth K Van Dril; Kayce M Shealy; Jennifer D Goldman
Journal:  Clin Diabetes       Date:  2021-01

6.  Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.

Authors:  Taichi Ikedo; Manabu Minami; Hiroharu Kataoka; Kosuke Hayashi; Manabu Nagata; Risako Fujikawa; Sei Higuchi; Mika Yasui; Tomohiro Aoki; Miyuki Fukuda; Masayuki Yokode; Susumu Miyamoto
Journal:  J Am Heart Assoc       Date:  2017-06-19       Impact factor: 5.501

Review 7.  The regulatory role of DPP4 in atherosclerotic disease.

Authors:  Lihua Duan; Xiaoquan Rao; Chang Xia; Sanjay Rajagopalan; Jixin Zhong
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

8.  Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials.

Authors:  Chrysi Koliaki; Nicholas Katsilambros
Journal:  Int J Environ Res Public Health       Date:  2019-12-24       Impact factor: 3.390

Review 9.  DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.

Authors:  Michael Razavi; Ying-Ying Wei; Xiao-Quan Rao; Ji-Xin Zhong
Journal:  Mil Med Res       Date:  2022-08-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.